


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**

**APPLICATION FOR CLINICAL TRIAL ON TQB3205 “PAN-KRAS INHIBITOR”  
APPROVED BY THE NMPA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that TQB3205 “pan-KRAS inhibitor”, a national Category 1 innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (“**CTTQ**”, a subsidiary of the Group), has received the clinical trial approval from China’s National Medical Products Administration (NMPA) for the intended treatment of advanced malignant tumors.

TQB3205 is an oral pan-KRAS inhibitor. Its core mechanism of action involves the binding to multiple KRAS-mutant proteins with high affinity, thereby blocking RAS activation by inhibiting SOS1-mediated nucleotide exchange in KRAS, and in turn suppressing the phosphorylation of downstream ERK. Accordingly, the process effectively inhibits the proliferation of various KRAS-mutant tumor cells.

The KRAS gene is the most frequently mutated gene within the RAS family. Approximately 30% of all cancer cases worldwide are associated with RAS gene mutations, with KRAS mutations accounting for 85% of all RAS mutations. Such mutations are prevalent in various cancers, including pancreatic cancer (90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%)<sup>[1-2]</sup>. However, KRAS mutation subtypes vary significantly across different tumor types, with common variants including G12C, G12V, G12D, and G13D<sup>[3-4]</sup>. Currently, all five KRAS inhibitors approved for marketing worldwide only target the G12C mutation subtype.

The Group's jointly developed KRAS G12C inhibitor, garsorasib (trade name: Anfangning (安方寧)), received marketing approval from China's NMPA in November 2024. Nonetheless, clinical needs in the field of KRAS remain highly unmet, thus necessitating pan-KRAS inhibitors which are capable of covering a broader range of mutation subtypes. The Group is committed to accelerating the clinical development of TQB3205 to overcome existing treatment limitations and provide novel therapeutic options for a broader patient population with advanced malignant tumors harboring KRAS mutations.

Sources:

- [1] Wang Y, You M, Wang Y. Alternative splicing of the K-RAS gene in mouse tissues and celllines[J]. *Exp Lung Res*, 2001, 27(3): 255-267.
- [2] Parikh K, Banna G, Liu SV, et al. Drugging KRAS: Current perspectives and state-of-art review[J]. *J Hematol Oncol*, 2022, 15(1): 152.
- [3] Kulkarni AM, Kumar V, Parate S, et al. Identification of new KRAS G12D inhibitors through computer-aided drug discovery methods[J]. *Int J Mol Sci*, 2022, 23(3): 1309.
- [4] O'Bryan JP. Pharmacological targeting of RAS: Recent success with direct inhibitors[J]. *Pharmacol Res*, 2019, 139: 503-511.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 11 March 2026

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*